Overview

Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this single arm, open label study is to evaluate the feasibility of pembrolizumab combined with radiation administered to the upper part of the vagina (vaginal cuff brachytherapy) followed by three cycles of pembrolizumab and chemotherapy in patients with endometrial cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of Oklahoma
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Carboplatin
Paclitaxel
Pembrolizumab